Currently out of the existing stock ratings of Srikripa Devarakonda, 51 are a BUY (96.23%), 2 are a HOLD (3.77%).

Srikripa Devarakonda

Work Performance Price Targets & Ratings Chart

Analyst Srikripa Devarakonda, currently employed at TRUIST, carries an average stock price target met ratio of 38.72% that have a potential upside of 35.21% achieved within 104 days.

Srikripa Devarakonda’s has documented 109 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 23-Apr-2025.

Wall Street Analyst Srikripa Devarakonda

Analyst best performing recommendations are on SRRK (SCHOLAR ROCK HOLDING CORP).
The best stock recommendation documented was for KYMR (KYMERA THERAPEUTICS) at 11/3/2023. The price target of $41 was fulfilled within 112 days with a profit of $26.73 (187.32%) receiving and performance score of 16.72.

Average potential price target upside

of $29.09 (15.95%) on ABBV (ABBVIE).
of $26.87 (152.41%) on KYMR (KYMERA THERAPEUTICS).
of $19.89 (36.51%) on INCY (YTE).

INCY yte AFMD Affimed NV CNST Constellation Pharmaceuticals NMTR 9 Meters Biopharma VSTM Verastem CYTK Cytokinetics KROS Keros Therapeutics KYMR Kymera Therapeutics LLY Eli Lilly and Company ABBV AbbVie BIIB Biogen EWTX Edgewise Therapeutics REGN Regeneron Pharmaceuticals SRRK Scholar Rock Holding Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jessica Fye (JPMORGAN)